The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Open accessAbstract
Sodium-glucose cotransporter (SGLT) 2 inhibitors increase urinary glucose excretion (UGE), leading to blood glucose reductions and weight loss. However, the impacts of SGLT2 inhibition on energy homeostasis and obesity-induced insulin resistance are less well known. Here, we show that empagliflozin, a SGLT2 inhibitor, enhanced energy expenditure and attenuated inflammation and insulin resistance in high-fat-diet-induced obese (DIO) mice. C57BL/6J mice were pair-fed a high-fat diet (HFD) or a HFD with empagliflozin for 16weeks. Empagliflozin administration increased UGE in the DIO mice, whereas it suppressed HFD-induced weight gain, insulin resistance, and hepatic steatosis. Moreover, empagliflozin shifted energy metabolism towards fat utilization, elevated AMP-activated protein kinase and acetyl-CoA carbolxylase phosphorylation in skeletal muscle, and increased hepatic and plasma fibroblast growth factor 21 levels. Importantly, empagliflozin increased energy expenditure, heat production, and the expression of uncoupling protein 1 in brown fat and in inguinal and epididymal white adipose tissue (WAT). Furthermore, empagliflozin reduced M1-polarized macrophage accumulation while inducing the anti-inflammatory M2 phenotype of macrophages within WAT and liver, lowering plasma TNFα levels and attenuating obesity-related chronic inflammation. Thus, empagliflozin suppressed weight gain by enhancing fat utilization and browning and attenuated obesity-induced inflammation and insulin resistance by polarizing M2 macrophages in WAT and liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 4×
“As the global rate of obesity has more than doubled in recent decades, the rates of associated metabolic disorders, including diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases, ctivated protein kinase; rophages; BAT, brown et-induced obese; EGP, orescence-activated cell test; H&E, haemat…”
BackgroundInfluentialObesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664
Kim, H. J., Park, S. Y., Choi, Y. J., Han, S. J., Lee, K. W., & Kim, D. J. (2013) · Hormone Research in Paediatrics · doi:10.1159/000348848 · Cited by 3,048
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.1964 · Cited by 2,230 · cited 2×
“Additionally, the infiltration of Th1 and CD8 T cells precedes M1-polarized macrophage recruitment, and the interactions between the T cells and macrophages constitute a maladaptive feedforward loop that leads to adipose inflammation and insulin resistance (Nishimura et al., 2009; Sell et al., 2012).”
BackgroundFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107 · cited 4×
“Obesity or ectopic fat accumulation induces an innate immune response with the subsequent recruitment of immune cells, which ultimately leads to the development of insulin resistance and nonalcoholic steatohepatitis (NASH).”
BackgroundInfluentialInagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478 · cited 1×
“FGF21 also activates the β3-adrenergic receptor inWAT and regulates the recruitment of beige adipocytes (Fisher et al., 2012).”
BackgroundMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 5×
“The loss of glucose calories induced by empagliflozin is consistent with increased lipid mobilization, causing a reduction in fat mass and weight (Ferrannini et al., 2016; Ferrannini et al., 2014).”
BackgroundInfluentialAlternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis
Nguyen, K. D., Qiu, Y., Cui, X., Goh, Y. P. S., Mwangi, J., David, T., Mukundan, L., Brombacher, F., Locksley, R. M., & Chawla, A. (2011) · Nature · doi:10.1038/nature10653 · Cited by 1,038
Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity
Brestoff, J. R., Kim, B. S., Saenz, S. A., Stine, R. R., Monticelli, L. A., Sonnenberg, G. F., Thome, J. J., Farber, D. L., Lutfy, K., Seale, P., et al. (2015) · Nature · doi:10.1038/nature14115 · Cited by 968 · cited 1×
“Paraffin-embedded eWAT, liver, and brown adipose tissue (BAT) sections were immunohistochemically stained for F4/80 and uncoupling protein (UCP) 1 as previously described (Brestoff et al., 2015; Zhuge et al., 2016).”
MethodCohen, P., Levy, J. D., Zhang, Y., Frontini, A., Kolodin, D. P., Svensson, K. J., Lo, J. C., Zeng, X., Ye, L., Khandekar, M. J., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.021 · Cited by 876
Qiu, Y., Nguyen, K. D., Odegaard, J. I., Cui, X., Tian, X., Locksley, R. M., Palmiter, R. D., & Chawla, A. (2014) · Cell · doi:10.1016/j.cell.2014.03.066 · Cited by 865
AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs
Hardie, D. G., Schaffer, B. E., & Brunet, A. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.013 · Cited by 859
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Ablation of CD11c-Positive Cells Normalizes Insulin Sensitivity in Obese Insulin Resistant Animals
Patsouris, D., Li, P.-P., Thapar, D., Chapman, J., Olefsky, J. M., & Neels, J. G. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.015 · Cited by 804 · cited 4×
“Obesity or ectopic fat accumulation induces an innate immune response with the subsequent recruitment of immune cells, which ultimately leads to the development of insulin resistance and nonalcoholic steatohepatitis (NASH).”
BackgroundInfluentialDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 2×
“Moreover, a recent study suggested that the inhibition of SGLT2with dapagliflozin directly triggered glucagon secretion in pancreatic alpha-cells (Bonner et al., 2015).”
BackgroundGrempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
AMPK—Sensing Energy while Talking to Other Signaling Pathways
Hardie, D. G. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.013 · Cited by 583
Wan, J., Benkdane, M., Teixeira-Clerc, F., Bonnafous, S., Louvet, A., Lafdil, F., Pecker, F., Tran, A., Gual, P., Mallat, A., et al. (2014) · Hepatology · doi:10.1002/hep.26607 · Cited by 558
Gowans, G. J., Hawley, S. A., Ross, F. A., & Hardie, D. G. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.019 · Cited by 531 · cited 2×
“Moreover, the inhibition of SGLT2 increases energy expenditure, leading to the increase of AMP/ATP (Gowans et al., 2013).”
BackgroundAdaptive immunity in obesity and insulin resistance
Sell, H., Habich, C., & Eckel, J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.114 · Cited by 486
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 391
Ota, T., Gayet, C., & Ginsberg, H. N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32752 · Cited by 376
Self-citationVallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Hui, X., Gu, P., Zhang, J., Nie, T., Pan, Y., Wu, D., Feng, T., Zhong, C., Wang, Y., Lam, K. S. L., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.004 · Cited by 349
Yamauchi, T., & Kadowaki, T. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.233 · Cited by 338
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D. R., Thomson, S. C., Koepsell, H., & Vallon, V. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00518.2013 · Cited by 310
Self-citationInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“The empagliflozin-induced hormonal change in relative hyperglucagonemia can be explained by reductions in glycaemia and insulin release, as insulin normally restrains glucagon secretion via paracrine action (Maruyama et al., 1984).”
BackgroundKitade, H., Sawamoto, K., Nagashimada, M., Inoue, H., Yamamoto, Y., Sai, Y., Takamura, T., Yamamoto, H., Miyamoto, K.-I., Ginsberg, H. N., et al. (2012) · Diabetes · doi:10.2337/db11-1506 · Cited by 292
Self-citationNi, Y., Nagashimada, M., Zhuge, F., Zhan, L., Nagata, N., Tsutsui, A., Nakanuma, Y., Kaneko, S., & Ota, T. (2015) · Scientific Reports · doi:10.1038/srep17192 · Cited by 261
Self-citationDevenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212
Yokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.040 · Cited by 195
Zhuge, F., Ni, Y., Nagashimada, M., Nagata, N., Xu, L., Mukaida, N., Kaneko, S., & Ota, T. (2016) · Diabetes · doi:10.2337/db16-0317 · Cited by 191
Self-citationObata, A., Kubota, N., Kubota, T., Iwamoto, M., Satō, H., Sakurai, Y., Takamoto, I., Katsuyama, H., Suzuki, Y., Fukazawa, M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1588 · Cited by 143
Qiang, S., Nakatsu, Y., Seno, Y., Fujishiro, M., Sakoda, H., Kushiyama, A., Mori, K., Matsunaga, Y., Yamamotoya, T., Kamata, H., et al. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0102-8 · Cited by 116
Ni, Y., Nagashimada, M., Zhan, L., Nagata, N., Kobori, M., Sugiura, M., Ogawa, K., Kaneko, S., & Ota, T. (2015) · Endocrinology · doi:10.1210/en.2014-1776 · Cited by 104
Self-citationRemogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice
Nakano, S., Katsuno, K., Isaji, M., Nagasawa, T., Buehrer, B. M., Walker, S., Wilkison, W. O., & Cheatham, B. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.02.005 · Cited by 89
Thomas, L. H., Grempler, R., Eckhardt, M., Himmelsbach, F., Sauer, A., Klein, T., Eickelmann, P., & Mark, M. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01518.x · Cited by 57
Neschen, S., Scheerer, M. F., Seelig, A., Huypens, P., Schultheiß, J., Wu, M., Wurst, W., Rathkolb, B., Suhre, K., Wolf, E., et al. (2014) · Diabetes · doi:10.2337/db14-0393 · Cited by 41
Cited by
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Metadata
- Authors
- Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 20
- Pages
- 137-149
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2619744261
- Cited by
- 493
- References
- 47
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.